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Stem cell therapy has emerged as a promising new area in regenerative medicine
allowing the recovery of viable tissues. Among the many sources of adult stem cells,
bone marrow-derived are easy to expand in culture via plastic adherence and their
multipotentiality for differentiation make them ideal for clinical applications. Interestingly,
several studies have indicated that MSCs expansion in vitro may be limited mainly due
to “cell aging” related to the number of cell divisions in culture. We have determined
that MSCs exhibit a progressive decline across successive passages in the expression
of stem cell markers, in plasticity and in the inflammatory response, presenting low
immunogenicity. We have exposed human MSCs after several passages to TLRs ligands
and analyzed their inflammatory response. These cells responded to pro-inflammatory
stimuli (i.e., NOS-2 expression) and to anti-inflammatory cytokines (i.e., HO1 and Arg1)
until two expansions, rapidly declining upon subculture. Moreover, in the first passages,
MSCs were capable to release IL1β, IL6, and IL8, as well as to produce active MMPs
allowing them to migrate. Interestingly enough, after two passages, anaerobic glycolysis
was enhanced releasing high levels of lactate to the extracellular medium. All these results
may have important implications for the safety and efficacy of MSCs-based cell therapies.
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INTRODUCTION
Mesenchymal stem cells (MSCs) are multipotent adult stem cells capable to differentiate into
mesenchymal-type cells (adipocytes, osteoblasts, and chondrocytes) but also myocytes, neurons,
endothelial cells, astrocytes and epithelial cells (Woodbury et al., 2002). These cells can be obtained
from bone marrow, umbilical cord blood, peripheral blood and adipose tissue (DelaRosa and
Lombardo, 2010). Nowadays, MSCs are an interesting tool for cell therapy and tissue repair
because they can be activated and recruited to sites of tissue damage where they regenerate new
tissues. Clinical applications require their expansion and differentiation in vitro before using in
patients to obtain an adequate number of cells. Despite the efforts that have been made, there are
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several problems associated to MSCs culture in vitro before using
them in regeneration therapies (Ikebe and Suzuki, 2014). Initially,
bone-marrow MSCs emerged as useful candidates due to their
potent self-renewal capacity. However, further studies of MSCs
populations indicated that in vitro expansion may be limited by
problems associated to their prolonged culture (Wei et al., 2013).
Since self-renewal is the process by which stem cells proliferate
and generate more stem cells, during the passages these cells
accumulate mutations in their genome with every round of DNA
replication. This fact remains controversial because MSCs are
capable to form colonies without maintenance of their initial
multipotentiality. Therefore, the determination of the number of
replications that can be done in vitro of MSCs before losing their
“stemness” properties is essential to achieve any success in future
clinical applications.
MSCs are being used in several clinical trials, mainly because
of their “low immunogenic” properties (Wei et al., 2013).
Accordingly, ex vivo expanded MSCs have been reported to
inhibit activation, proliferation and function of immune cells
through cell contact mechanisms and by soluble factors secreted
by MSCs in response immune cells cross-talk (Di Nicola et al.,
2002; Zhang et al., 2004; Corcione et al., 2006). Interestingly,
bone marrow-derived MSCs express several TLRs, highlighting
the presence of functional TLR2, TLR3, and TLR4 which can be
regulated by several cellular contexts, such as hypoxic conditions
(Mo et al., 2008) or viral transduction (Chen et al., 2009).
Moreover, engagement of these receptors with specific ligands
resulted in the activation of signaling pathways (i.e., MAPKs
and PI3K) and transcription of NF-κB-dependent genes, such
as COX-2, IL6, and IL8 (Lombardo et al., 2009). Nevertheless,
the response of MSCs to inflammatory stimuli remained to be
determined. Thus, is has become essential the understanding of
the immune behavior of these cells in vitro.
Another interesting but less understood aspect of MSCs is
their ability to migrate from bone marrow or peripheral blood
into damaged tissues. A key requirement for cells to reach
distant target sites is the ability to traverse the extracellular
matrix which is present between cells of all tissue types (Kalluri,
2003).Migrating cells need to express proteolytic enzymes known
as matrix metalloproteinases (MMPs), which are involved in
many physiological or pathological conditions, being MMP2,
and MMP9 the most important in MSC context (Visse and
Nagase, 2003; Koippallil Gopalakrishnan Nair et al., 2015). The
biosynthesis and activity of MMPs are associated with the
invasive capacity of various cell types (Egeblad and Werb, 2002).
These proteins are secreted in cells as inactive zymogens which
are rapidly complexed by their specific endogenous inhibitors,
the tissue inhibitors of metalloproteinases (TIMPs). It has been
described that both TIMP1 and TIMP2 can be secreted by MSCs
promoting an anti-metastatic phenotype (Itoh et al., 2001; Clarke
et al., 2015). Thus, as the balance of MMP/TIMP could modulate
the migratory capacity of MSC, is it important to determine if
there is some kind of modulation along the passages. If MSCs
are unable to reach the target tissue, then these cells lose their
potential application in regenerative medicine.
Another key factor is the stability of the metabolic
profile of MSCs after successive replications. Recent studies
have revealed a shift in the balance between glycolysis,
mitochondrial oxidative phosphorylation and oxidative stress
during the maturation of adult stem cells, and during the
reprogramming of somatic cells to pluripotency (Pattappa
et al., 2011). Thus, it is necessary to define and ensure the
“stemness” properties of these human cells upon expansion.
These insights shed light to the controversial use of MSCs
to enhance regeneration and the treatment of degenerative
diseases.
RESULTS
The main interest to study MSCs is their promising role in tissue
regeneration because of their multipotentiality. However, one
of the main problems associated to MSCs is that they suffer
genetic alterations after several divisions in vitro augmenting
their genomic instability (Ross et al., 2011). Therefore, prior
to widespread use of these cells in regenerative medicine, it
is important to gain understanding of the specific changes
that occur after expansion in successive passages. It has been
described thatmurine or porcine bonemarrow-derivedMSCs are
induced to differentiate into “myogenic cells” in vitro with 5-aza-
2′-deoxycytidine (5-Aza-dC) treatment (Moscoso et al., 2005).
Moreover, MSCs from adult human exposed to this compound
are capable to express cardiac-specific genes (Xu et al., 2004).
To test this, cells from 11 different donors in culture for 1–4
passages (P1–P4) were exposed to 10µM of 5-Aza-dC for 24 h
or 5 days. After 5 days of 5-Aza-dC treatment, the surviving cells
began to proliferate and differentiate. Those of the first passage
(P1) exhibited a morphological transition from a fibroblast-
like shape to a stick-like appearance exhibiting several primitive
myofilaments (Figure 1A); however, this effect disappeared in
subsequent passages. We also determined the expression of
cardiac markers, such as cardiac myosin (β-MHC) or troponin
T (cTnT) by PCR (Figure 1B), Western blot (Figures 1C,D),
and immunofluorescence (Figures 1E,F). 5-Aza-dC treatment
induced higher levels of both cardiac proteins (at mRNA level
also for β-MHC, Figure 1B) at P1 but this effect was missing at
P4. Collectively, these results indicated that the capacity of MSCs
to underwent cardiomyocyte differentiation in response to 5-
Aza-dC treatment rapidly disappear after culture progression. To
corroborate the “stemness” phenotype of the MSCs, we analyzed
the expression of proteins considered as markers of pluripotency
(Wilson et al., 2004; Wang et al., 2013) in all passages. Some of
these markers exhibited a rapid drop in protein levels after P1
(Nanog) or maintained a significant expression along passages,
such as occurred for KLF4 and c-Myc, probably for this reason
cells retained the proliferative capacity (Figures 2A,B). These
data suggest thatMSCs were capable tomaintain their “stemness”
properties in culture during the initial fourth passages, being
advisable their use within this period for regenerative medicine
purposes.
Several groups recognized an immunosuppressive activity for
MSC (Ren et al., 2008; Han et al., 2012). However, despite
broad research in recent years, whether MSCs are capable to
express inflammatory genes in response to pro-inflammatory
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FIGURE 1 | MSCs exposure to 5′-aza-2′-deoxycytidine (5-aza-dC) induces in vitro differentiation to a “myogenic phenotype” in P1 (first passage) but
this effect is lost at P4. The morphology of MSCs changed after 5-aza-dC exposure from fibroblast-like to form a stick-like morphology and several primitive
myofilaments were detected in P1 (A). The mRNA levels (qPCR) of the specific marker cardiac myosin (β-MHC) were significantly augmented after 5-aza-dC treatment
in P1 without changes in cardiac troponin (cTnT) levels. No changes were detected in P4 (B). The expression of β-MHC and cTnT was enhanced at the protein level
(Western blot; C,D) and by immunofluorescence analysis, using DAPI (nuclear) and phalloidin (actin) staining (E,F), after 5-aza-dC in P1 but was missing in P4. *p <
0.05; **p < 0.01 vs. the untreated cells (0 h).
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FIGURE 2 | The expression of some “stem cell markers” decays in MSCs after prolonged number of replications in vitro. MSCs were maintained in
culture and the protein levels of the “stem cell markers” c-Myc, KLF4 and Nanog was analyzed by Western blot (A) and by immunofluorescence (nuclei stained with
DAPI, B). Values are the mean ± SD of the band ratios (A) or the green fluorescence (B). *p < 0.05; vs. P1 cells.
stimuli remains controversial. We have exposed these cells
throughout the successive passages to classical pro- and anti-
inflammatory factors and analyzedMSCs responses. Cells treated
with LPS (200 ng/ml) or IFN-γ (20 ng/ml) plus LPS showed
increased levels of NOS-2 at P1 that rapidly declined in the
consecutive expansions. Moreover, nitrite accumulated in the
culture medium in agreement to NOS-2 levels (Figure 3A).
Interestingly, COX-2 was not significantly increased from P1
and P4 after pro-inflammatory stimulation as well as PGE2
levels that remained unchanged (Figure 3B). Furthermore,MSCs
express low but constant levels of receptors for IL4 and IL13
(IL13Rα1 subunit as marker; downregulated by IL4 and IL13
at P4) and inducible levels of IL10R that increased after IL10
exposure (Figure 4A), all three cytokines involved in the anti-
inflammatory phenotype of immune cells, such as macrophages.
Moreover, when MSCs were exposed to IL4 plus IL13 or
IL10 (20 ng/ml) and the levels of hemeoxygenase-1 (HO1) and
arginase-1 (Arg1) were analyzed, both proteins exhibited a
cytokine dependent rise at P1, declining in P4 (Figures 4B–D).
The immunomodulatory effects of MSCs are jointly executed
by both secretory factors and direct cell-to-cell contacts
(Hoogduijn et al., 2010) and the in vitro inflammatory profile
of human MSC has been previously analyzed (Schinköthe et al.,
2008). Here we have determined the accumulation of several
cytokines by MSC along the passages. Interestingly, MSC release
low but constant levels of IL1β along the passages (≤200
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FIGURE 3 | MSCs treatment with pro-inflammatory stimulus induces the expression of NOS-2 but not COX-2 as well as the accumulation of nitrites in
the culture medium. MSCs were treated with LPS (200 ng/ml) or IFN-γ (20 ng/ml) plus LPS for 24 h as indicated and the protein levels of NOS-2 (A, left panel) and
COX-2 (B, left panel) were analyzed both in P1 and P4. GAPDH was used as normalization protein. The levels of nitrite and PGE2 in the culture medium (A,B, right
panels) were determined at P1 and P4. The histograms show the mean ± SD. *p < 0.05; **p < 0.01 vs. control cells.
pg/ml), exhibiting a significant induction after LPS plus IFN-
γ challenge (at P2 and P3; Figure 5A). Regarding IL6 and IL8
levels, MSCs release higher levels of these cytokines which are
strongly induced by the treatment with LPS or IFN-γ plus LPS
up to P3, diminishing their levels to basal in successive passages
(Figures 5B,C).
An additional aspect of the therapeutic potential of MSCs
involves the capacity of these cells to extravasate after systemic
administration that has been associated to the expression of
MMP2/MMP9 (Ries et al., 2007) and which activity is controlled
by the inhibitor proteins TIMP (De Becker et al., 2007). We
determined that along the passages, MSCs express lesser levels of
mRNA of MMP9 but significantly higher quantity of TIMP1 and
TIMP2 (Figures 5D,E), suggesting that the migratory capacity
rapidly drops after subculturing the cells, reducing the capacity
to reach target tissues after inoculation. Moreover, the MMPs
activity determined by zymography also exhibit an expansion-
dependent decrease across passages (Figure 5F). According to
this, the migratory capacity of MSCs determined in a “wound
healing” assay was elevated in P1 but is significantly lower in P4
both at 24 h and 7 days (Figure 5G).
Moreover, since metabolic rewiring is important in the
functional responses of proliferating and immune cells (Pattappa
et al., 2011), we have evaluated glucose consumption and lactate
release by MSCs after confluence at each expansion cycle. As
Figure 6A shows, MSCs metabolize glucose more actively at
P1 and P2, whereas a drop at successive passages is observed.
Regarding lactate, an increase in the ratio of lactate accumulation
vs. glucose consumption is progressively observed from P1 to P4,
indicating that MSCs are increasing anaerobic metabolism along
the passages at the time that challenge with pro-inflammatory
cytokines potentiates this metabolic shift regardless the passage
(Figure 6A). Moreover, the levels of glucose transporters GLUT-
4, HK-1, and HK-2 drop along the passages, in agreement
with the decrease in glucose usage (Figure 6B), lacking the
expression of the PFKFB3, a key enzyme in the positive
regulation of the upper part of glycolysis (Mahlknecht et al.,
2003). Indeed, the improvement of glucose consumption after
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FIGURE 4 | MSCs treatment with IL10 or IL4+IL13 increases the protein levels of HO1 and Arg1. MSCs were exposed to IL4, 10, or 13 as indicated and
mRNA levels of IL13Rα1 and IL10R were analyzed by qPCR (A) after challenge at P1 and P4. HO1 (B,C) and Arg1 (D) protein levels were induced by IL10 or
IL4+IL13 incubation in P1 diminishing in the subsequent. The histograms show the mean ± SD. *p < 0.01 vs. the control condition.
pro-inflammatory challenge parallels the expression of HK-
1 and -2 at P1 and P4, being PFKFB3 absent under these
conditions (Figure 6C). These data indicate a significant shift
in energy metabolism across the expansion of the MSC in
culture.
DISCUSSION
Most of human tissues and organs do not regenerate
spontaneously, justifying why cell therapy is today a significant
issue in tissue and organ repair strategy, leading to the concept
of “regenerative medicine” as an exciting new area of biomedical
research (Bajada et al., 2008; Wu and Hochedlinger, 2011; Sykova
and Forostyak, 2013). In this regard, adult MSCs represent an
innovative tool for cell-based therapy of degenerative disorders
(Joyce et al., 2010; Uccelli et al., 2011), chronic inflammation
(González et al., 2009), autoimmune diseases (Constantin et al.,
2009) and allograft rejection (Ringden et al., 2006). These cells
have great plasticity but their physio-pathological properties
remain poorly understood. Therefore, a better characterization
of the mechanisms that mediate or modulate the therapeutic
potency of MSCs is important from both physiological and
clinical points of view.
MSCs have been considered an appealing source for cell
therapy because they can be easily obtained and expanded in
vitro. The number of clinical trials using MSCs has been rising
since 2004; however, although the use of MSCs in clinical
settings began with high enthusiasm in many countries, with
China, Europe and US leading the way (http://clinicaltrial.cn),
numerous scientific issues remain to be resolved before the
establishment of clinical standards and governmental regulations
(Wei et al., 2013). The heterogeneity of MSCs preparations in
vitro has been considered as one of the major challenges that
significantly impair progress in basic and translational MSC
research as well as in the development of MSC therapies (Jones
and Schäfer, 2015). Recent studies showed that the ability of
expansion and differentiation of MSC may depend on several
factors, such as donor’s age, gender and in vitro cellular aging
on the phenotypic, functional and molecular characteristics of
MSCs (Brooke et al., 2008; Katsara et al., 2011). In this context
it is essential to determine the maximal number of replications
that are possible to maintain MSCs in culture without loss of
stem and regenerative properties. Our results indicate that MSCs
Frontiers in Physiology | www.frontiersin.org 6 November 2016 | Volume 7 | Article 548
Prieto et al. hMSC Expansion-Dependent Inflammatory Profile
FIGURE 5 | MSCs release some cytokines in vitro such as IL1β, IL6, and IL8 in different inflammatory scenarios and their migration potential is
maintained only until P2. MSCs were treated for 24 h as indicated and the presence of IL1β, IL6, and IL8 were measured in their supernatants (A–C). The mRNA
levels of MMP2 and MMP9 (D) and of TIMP1 and TIMP2 (E) were analyzed after treatments to compare from P1 to P4. The relative activity of MMP2 was analyzed by
zymography in gel (F) in control and LPS+IFN treated cells from P1 to P4. The migration capacity of cells was measured using a “wound healing” assay (G) at 0, 24 h
and 7days in control cells at P1 and P4. *p < 0.05; **p ≤ 0.01 vs. the control or P1 condition.
obtained from human bone marrow of healthy donors, maintain
their stem properties only in the first passages, with specific
and reliable differential responses from P1 to P4 passages, losing
their pluripotency in the subsequent expansions. As an example,
we have observed a better capacity of differentiation into a
“myogenic-like” phenotype at P1. In addition, these cells express
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FIGURE 6 | MSCs efficiently metabolized glucose until the P4 producing higher levels of lactate in consequence. MSC were treated as indicated and the
glucose (left panel) and lactate (right panel) levels were determined in the supernatants from P1 to P4 (A). Protein levels of several metabolic enzymes as GLUT-1,
GLUT-4, HK-I, HK-II, and PFKFB3 were determined from P1 to P4 in control conditions (B). MSCs were treated as indicated (C) and protein levels of HK-I, HK-II and
PFKFB3 were analyzed in P1 and P4. GAPDH was used as a normalization protein in both panels. *p < 0.05 vs. P1 condition.
several “stemness” markers, such as c-Myc, KLF4 and Nanog,
but the levels of some of these proteins diminished significantly
with the successive passages suggesting that these cells lose their
growth capacity after prolonged culture. Special mention deserve
KLF4 and c-Myc that, perhaps after forcing the cells to proliferate,
are progressively over-represented in the P1–P4 expansion. Thus,
we propose that MSCs must not be replicated more than two
or three passages in vitro before using in regenerative medicine
since this fact ensures the maintenance of pluripotency and,
perhaps favors a positive interaction with the damaged tissue that
determined the commitment of the engrafted MSC.
Another critical aspect to be addressed in MSCs physiology
is the immunological response of these cells by itself, which
is basic to understand their response to several factors that
can be present in the damaged tissue scenario. We have
determined that depending on the stimulation, these cells
presented higher protein levels of NOS-2, HO1 and Arg1
as well as an increased release of inflammatory cytokines
to the culture medium. This fact highlights that, despite its
low immunogenicity, MSCs have certain capacity to respond
according to the local immune context. Indeed, the capacity
to respond to classic pro-inflammatory (LPS and IFN-γ) and
anti-inflammatory and pro-resolution factors (IL4, IL10, and
IL13) of “professional” immune cells (Rodriguez-Prados et al.,
2010) is retained only during P1 and P2 cycles. Although it
is not possible to preclude the microambience to which these
cells are confronted during therapeutic administration, the fact
that classic immunomodulators, such as the prostanoids derived
from cyclooxygenase 2 (i.e., PGE2) also accumulate across cell
expansions, it is possible to suggest that immunotolerance
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progresses when the cells are used at passages higher than
2. Regarding metabolic adaptations, it has been shown that
the initial induction of human and mouse pluripotent stem
cell differentiation is associated to enhanced glycolysis but
driven to production of acetyl-CoA and acetate, in addition
to lactate (Moussaieff et al., 2015). Here we show that at
late passages (P3–P4), glucose consumption is decreased, but
lactate released is enhanced suggesting in impaired use of these
substrates for TCA and acetate synthesis. In agreement with
these results, the lesser glycolytic usage may trigger a loss of
acetate synthesis and histone acetylation, reducing the capacity
to maintain a pluripotent state (Hussein et al., 2014; Moussaieff
et al., 2015). Moreover, we have proved that MSCs have a high
migratory potential in the first passages, mainly associated to
MMP2 activity, but this capacity rapidly declines after successive
passages. This fact may be related to the significant decrease in
the expression of MMPs as well as an augmentation of TIMP1
and TIMP2 levels from P2 in advance that are associated to a
decreased collagenase activity of MMPs. These observations need
to be considered when modulation of the migratory capacity
of the MSCs is a central issue in the specific application for
regenerative purposes since, after passage 2, the ability to migrate
is negligible.
In addition to this, our data suggest that the glucose
metabolism of MSC also experiences significant changes upon
culture, moving toward a more anaerobic phenotype: whereas
glucose consumption decreases after P2, the release of lactate
increases suggesting a lesser capacity to use glucose through the
TCA cycle. Although it can be proposed that histone acetylation
is decreased under these conditions, the significance of this
shift is at present unknown and further work is necessary
to evaluate how energy metabolism changes after in vitro
expansion of the cells, but the possibility exists to manipulate this
central determinant of cell fate (i.e., under hypoxic conditions,
restricting glucose, fatty acids and amino acid metabolism)
to improve the regenerative capacity of MSC. Nevertheless,
before MSC-based therapeutics can be applied in the clinic,
more research is necessary to understand their behavior upon
transplantation as well as the mechanisms of their interaction
with the diseased microenvironment (Stoltz et al., 2015). The
enormous advantages that offer the MSC for cell and/or tissue
replacement after transplantation (autologous administration, in
vitro manipulation, etc.), and their prolonged clinical use raises
heavy debates in the fields of tissue engineering and regenerative
medicine to date. Unraveling specific applications of this the
therapeutic option may open new ways in this area, but a better
understanding of their basic biology is essential to provide the
rationale to these approaches.
MATERIALS AND METHODS
Materials
LPS was from Sigma-Aldrich, IFN-γ, IL4, IL10, IL13 were from
PeproTech. 5-Aza-2′-deoxycytidine (5-Aza-C) was from Sigma-
Aldrich. Antibodies were from Santa Cruz Biotech, Ambion,
Millipore, Abcam and Cell Signaling Tech (see Table 1). PCR
probes were from Invitrogen. Fluorescent secondary antibodies
TABLE 1 | Antibodies used in western blot and immunofluorescence
assays.
Antibody Supplier Number Working use
Arg1 Santa cruz biotechnology sc-20150 1:1000
B-MHC Abcam ab15 1:1000
c-Myc Cell signaling technologies 5605 1:1000
COX-2 Santa cruz biotechnology sc-1747 1:500
cTnT Abcam ab10214 1:1000
GAPDH Ambion AM4300 1:20,000
GLUT-1 Abcam Ab40084 1:1000
HK-1 Cell signaling technologies 2014 1:1000
HO1 Millipore AB1248 1:2000
KLF4 Cell signaling technologies 4038 1:1000
NANOG Cell signaling technologies 4903 1:1000
NOS-2 Santa cruz biotechnology sc-650 1:500
PFKFB3 Santa cruz biotechnology sc-10091 1:500
were from Molecular Probes. Tissue culture dishes were from
Falcon and tissue culture media were from Gibco-Invitrogen.
Human Mesenchymal Stem Cell Culture
Bone marrow samples were obtained from iliac crests aspirates
over heparin from 11 healthy volunteers (6 men, 5 women)
after informed consent, and were used in accordance with
the procedures approved by the human experimentation and
ethics committees of Hospital General Universitario Gregorio
Marañón (Madrid). The mean of age was 50.5 ± 19.6 years.
Mononuclear cells were isolated by centrifugation through
1.073 g/ml Ficoll at 1100 g for 30min, rinsed twice with PBS,
counted and seeded at 1.5 × 105 cells per cm2 in complete
medium (DMEM, 10% FBS, 5% HS, 100U/ml penicillin and
streptomycin) at 37◦C in a humidified 5% CO2 air atmosphere.
Three days later, non-adherent cells were removed by replacing
the medium. After 10 days in culture, adherent cells formed
homogenous colonies. The adherent cells were resuspended
after trypsin treatment and re-plated at a density of 8,000/cm2
(approximately 1:3). The medium was changed every 3 days
and these cells were considered as “multipotent mesenchymal
stromal cells” (MSCs). MSCs expressed ≥95% of CD105, CD73,
and CD90 and lacked the expression (≤2% positives) of CD45,
CD34, CD14, CD11b, CD79α, CD19, and HLA class two, as
analyzed by flow cytometry. Moreover, these cells differentiate
into osteoblasts, adipocytes and chondroblasts under standard
in vitro differentiation conditions following the criteria of the
International Society for Cellular Therapy (ISCT) (Dominici
et al., 2006). MSCs were grown and expanded for at least 4
passages in culture. Morphologically, MSCs were defined by a
fibroblast-like appearance.
Myogenic Differentiation of MSCs In vitro
Cells were seeded in DMEM plus 10% FBS and exposed to
10µMof 5-Aza-C for 24 h. To prevent cell death from prolonged
5-Aza-C exposure, cells were washed twice with PBS and the
medium was replaced. Cells were maintained in the absence
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or 5-Aza-C for 5 days to allow the complete differentiation to
cardiomyocytes.
Preparation of Total Cell Extracts
Cells were homogenized at 4◦C in a medium containing 10mM
Tris-HCl, pH 7.5; 1mM MgCl2, 1mM EGTA, 10% glycerol,
0.5% CHAPS and proteases and phosphatases inhibitors cocktails
(Sigma #P8340, #P5726, #P0044). The extracts were vortexed
for 30min at 4◦C and after centrifuging for 15min at 13,000 g,
the supernatants were stored at −20◦C. Protein levels were
determined with Bradford reagent (Bio-Rad #500-0006).
Western Blot Analysis
Equal amounts of protein (20–40µg) were loaded and size-
fractionated onto 8–12% SDS-PAGE and transferred to a PVDF
membrane (Bio-Rad #170-4157). After blocking with 5% non-
fat dry milk and incubation with the corresponding Abs
(Table 1) the blots were developed by ECL protocol and different
exposition times were performed for each blot to ensure the
linearity of the band intensities. Values of densitometry were
determined using Image J software.
Immunofluorescence Microscopy
Cells were seeded for 16–24 h into sterile 8-wells Chamber
Slides (Falcon). After treatments, cells were fixed with 2%
paraformaldehyde for 10min, permeabilized in iced methanol
and incubated with 3% BSA for 30min (Sigma #A2153). After
incubating with Ab against cardiac myosin, troponin T, c-Myc,
KLF-4 and Nanog (see Table 1) at 4◦C for 18 h, cells were
washed with PBS followed by incubation with Alexa 488 anti-
rabbit secondary antibody (1:500, Molecular Probes) and DAPI
1:1000 for 20min. Coverslips were mounted in ProLong R© Gold
Antifade reagent (Life technologies #P36930) and examined
using a confocal microscope Leica PCS SP5.
Prostaglandin E2, Glucose and Lactate
Determinations
Prostaglandin E2 was measured in the culture media with a
commercial kit from Arbor Assays, following the manufacturer’s
instructions. Glucose and lactate were determined using
commercial kits from Biosystems and SpinReact, SA, following
the manufacturer’s instructions.
Detemination of NO Levels
The amount of nitrites in the culture medium was measured after
reduction of nitrate to nitrite and quantification of nitrite using a
previous protocol (Rodriguez-Prados et al., 2010)
DIaplex Human Th1/Th2/Inflammation Kit
The quantification of multiple human cytokines (IFN-
γ, TNF-α, IL1β, IL2, IL4, IL6, IL8, IL10, IL12p70, and
IL17A) was performed in culture supernatants by flow
cytometry using a commercial kit from Diaclone (Gen-
Probe) following the manufacturer’s instructions. This is
a multiplexed fluorescent bead-based immunoassay for
the simultaneous quantification of multiple analytes from
a single sample, utilizing bead populations with distinct
fluorescence intensities. Once the data were acquired, we
performed the data analysis using the specific DIAplex Pro
software supplied by www.genprobe.com, as indicated in the
website.
Human Interleukin ELISA Kits
Data from diaplex were verified using specific human ELISA
kits to quantify IL6 and IL8 (Abcam #ab46042 and #ab46032,
respectively). These assays were carried out following the
manufacturer’s instructions.
PCR
RNA was extracted from cells using TRI Reagent R© solution
(Ambion #AM9738) and 1µg was reverse-transcribed
into cDNA using the Transcriptor first strand cDNA
synthesis kit (Roche #04897030001). Then, PCR reaction
was performed with this template cDNA adding FastStart
Universal SYBR Green Master (Roche #04913850001)
and specific primers (Table 2) in a MyIQ thermocycler
(Bio-Rad).
Zymography Assay
Supernatants were incubated for 1 h RT in loading buffer without
reducing agents (50mM Tris HCl pH6.8, 8% glycerol, 2% SDS,
0.004% bromophenol blue). After electrophoresis at 50V ON
4◦C in a resolving acrylamide gel (11% for MMP2 and 7.5%
for MMP9) containing 1 mg/ml gelatin, gel was incubated
in activation buffer (50mM Tris-HCl pH 7.4, 0.2M NaCl,
5mM CaCl2, 1% TritonX100, 0.02% NaN3) at 37
◦C ON to
allow that renatured MMPs in the gel digest their substrates.
After incubation, the gel was stained with 0.5% Comassie R©
TABLE 2 | Primers used in qPCR analysis.
PRIMER Forward Reverse
β-MHC GGGATAACCAGGGGAAGCACCAAGA ACTTGCGGAGGTACTGGGCCG
cTnT AAGCCCAGGTCGTTCATGCCC CCATGCGCTTCCGGTGGATGT
IL13Rα1 CCGCGCCTACGGAAACTC CGGGTGGATTCCATGTCCATA
IL10R CTGAAGAGCCCCAGTTCCTC TCCCGCTGTCTGTGCTATTG
MMP2 TACAGGATCATTGGCTACACACC GGTCACATCGCTCCAGACT
TIMP2 ACAGGCGTTTTGCAATGCA GGGTTGCCATAAATGTCGTTTC
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blue for 30min RT and then washed with 30% ethanol/10%
acetic acid solution for at least 1 h RT. Finally MMPs were
detected as clear bands against a blue background of undegraded
substrate that can be quantified by densitometry using Image J
software.
“Wound Healing” Migration Assay
Cells were seeded and culture until confluence. Using a pipette
tip make a straight scratch, simulating a wound. Then, several
images of the same area were taken at the beginning (time 0) and
after 24 h and 7 days during migration to detect cells closing the
wound. Themigration rate was quantified using Image J software.
Statistical Analysis
The values in graphs correspond to themean± SD. The statistical
significance of differences between mean sample values was
estimated with a Student’s t-test for unpaired observations. A
p≤0.05 value was considered as statistically significant.
AUTHOR CONTRIBUTIONS
PP, PS, FF, and LB conceived and designed the experiments,
PP, MFV, MFS, and VT performed the experiments, PP and
LB analyzed the data and PP, MFV, PM, and LB wrote the
paper.
FUNDING
This work was funded by grants SAF2014-52492R and RTC2015-
3741 from MINECO; RD12/0042/0019 and Ciberehd are funded
by the Instituto de Salud Carlos III, and FEDER.
ACKNOWLEDGMENTS
The authors would like to thanks to Dolores Morales (SIDI-
UAM) for the excellent technical assistance with the confocal
microscopy images.
REFERENCES
Bajada, S., Mazakova, I., Richardson, J. B., and Ashammakhi, N. (2008). Updates on
stem cells and their applications in regenerative medicine. J. Tissue Eng. Regen.
Med. 2, 169–183. doi: 10.1002/term.83
Brooke, G., Tong, H., Levesque, J. P., and Atkinson, K. (2008). Molecular
trafficking mechanisms of multipotent mesenchymal stem cells derived from
human bone marrow and placenta. Stem Cells Dev. 17, 929–940. doi:
10.1089/scd.2007.0156
Chen, G. Y., Shiah, H. C., Su, H. J., Chen, C. Y., Chuang, Y. J., Lo, W. H., et al.
(2009). Baculovirus transduction of mesenchymal stem cells triggers the toll-
like receptor 3 pathway. J. Virol. 83, 10548–10556. doi: 10.1128/JVI.01250-09
Clarke, M. R., Imhoff, F. M., and Baird, S. K. (2015). Mesenchymal stem cells
inhibit breast cancer cell migration and invasion through secretion of tissue
inhibitor of metalloproteinase-1 and -2. Mol. Carcinog. 54, 1214–1219. doi:
10.1002/mc.22178
Constantin, G., Marconi, S., Rossi, B., Angiari, S., Calderan, L., Anghileri, E.,
et al. (2009). Adipose-derived mesenchymal stem cells ameliorate chronic
experimental autoimmune encephalomyelitis. Stem Cells 27, 2624–2635. doi:
10.1002/stem.194
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F.,
et al. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood
107, 367–372. doi: 10.1182/blood-2005-07-2657
De Becker, A., Van Hummelen, P., Bakkus, M., Vande Broek, I., De Wever,
J., De Waele, M., et al. (2007). Migration of culture-expanded human
mesenchymal stem cells through bone marrow endothelium is regulated
by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3.
Haematologica 92, 440–449. doi: 10.3324/haematol.10475
DelaRosa, O., and Lombardo, E. (2010). Modulation of adult mesenchymal
stem cells activity by toll-like receptors: implications on therapeutic potential.
Mediators Inflamm. 2010:865601. doi: 10.1155/2010/865601
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci,
P., et al. (2002). Human bone marrow stromal cells suppress T-lymphocyte
proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99,
3838–3843. doi: 10.1182/blood.V99.10.3838
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause,
D., et al. (2006). Minimal criteria for defining multipotent mesenchymal
stromal cells. The International Society for Cellular Therapy position
statement. Cytotherapy 8, 315–317. doi: 10.1080/14653240600855905
Egeblad, M., andWerb, Z. (2002). New functions for the matrix metalloproteinases
in cancer progression. Nat. Rev. Cancer 2, 161–174. doi: 10.1038/nrc745
González, M. A., Gonzalez-Rey, E., Rico, L., Büscher, D., and Delgado, M.
(2009). Adipose-derived mesenchymal stem cells alleviate experimental colitis
by inhibiting inflammatory and autoimmune responses. Gastroenterology 136,
978–989. doi: 10.1053/j.gastro.2008.11.041
Han, Z., Jing, Y., Zhang, S., Liu, Y., Shi, Y., and Wei, L. (2012). The role of
immunosuppression of mesenchymal stem cells in tissue repair and tumor
growth. Cell Biosci. 2:8. doi: 10.1186/2045-3701-2-8
Hoogduijn, M. J., Popp, F., Verbeek, R., Masoodi, M., Nicolaou, A., Baan, C.
(2010). The immunomodulatory properties of mesenchymal stem cells and
their use for immunotherapy. Int. Immunopharmacol. 10, 1496–1500. doi:
10.1016/j.intimp.2010.06.019
Hussein, S. M., Puri, M. C., Tonge, P. D., Benevento, M., Corso, A. J., Clancy, J.
L., et al. (2014). Genome-wide characterization of the routes to pluripotency.
Nature 516, 198–206. doi: 10.1038/nature14046
Ikebe, C., and Suzuki, K. (2014). Mesenchymal stem cells for regenerative therapy:
optimization of cell preparation protocols. Biomed Res. Int. 2014:951512. doi:
10.1155/2014/951512
Itoh, Y., Takamura, A., Ito, N., Maru, Y., Sato, H., Suenaga, N., et al. (2001).
Homophilic complex formation ofMT1-MMP facilitates proMMP-2 activation
on the cell surface and promotes tumor cell invasion. EMBO J. 20, 4782–4793.
doi: 10.1093/emboj/20.17.4782
Jones, E., and Schäfer, R. (2015). Where is the common ground between bone
marrow mesenchymal stem/stromal cells from different donors and species?
Stem Cell Res. Ther. 6, 143. doi: 10.1186/s13287-015-0144-8
Joyce, N., Annett, G., Wirthlin, L., Olson, S., Bauer, G., and Nolta, J. A. (2010).
Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen.
Med. 5, 933–946. doi: 10.2217/rme.10.72
Kalluri, R. (2003). Basement membranes: structure, assembly and role in tumour
angiogenesis. Nat. Rev. Cancer 3, 422–433. doi: 10.1038/nrc1094
Katsara, O., Mahaira, L. G., Iliopoulou, E. G., Moustaki, A., Antsaklis, A.,
Loutradis, D., et al. (2011). Effects of donor age, gender, and in vitro cellular
aging on the phenotypic, functional, and molecular characteristics of mouse
bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 20, 1549–1561.
doi: 10.1089/scd.2010.0280
Koippallil GopalakrishnanNair, A. R., Pandit, H.,Warty, N., andMadan, T. (2015).
Endometriotic mesenchymal stem cells exhibit a distinct immune phenotype.
Int. Immunol. 27, 195–204. doi: 10.1093/intimm/dxu103
Lombardo, E., DelaRosa, O., Mancheño-Corvo, P., Menta, R., Ramírez, C., and
Büscher, D. (2009). Toll-like receptor-mediated signaling in human adipose-
derived stem cells: implications for immunogenicity and immunosuppressive
potential. Tissue Eng. Part A 15, 1579–1589. doi: 10.1089/ten.tea.2008.0340
Mahlknecht, U., Chesney, J., Hoelzer, D., and Bucala, R. (2003). Cloning and
chromosomal characterization of the 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase-3 gene (PFKFB3, iPFK2). Int. J. Oncol. 23, 883–891 doi:
10.3892/ijo.23.4.883
Frontiers in Physiology | www.frontiersin.org 11 November 2016 | Volume 7 | Article 548
Prieto et al. hMSC Expansion-Dependent Inflammatory Profile
Mo, I. F., Yip, K. H., Chan, W. K., Law, H. K., Lau, Y. L., and Chan, G. C. (2008).
Prolonged exposure to bacterial toxins downregulated expression of toll-like
receptors in mesenchymal stromal cell-derived osteoprogenitors. BMC Cell
Biol. 9:52. doi: 10.1186/1471-2121-9-52
Moscoso, I., Centeno, A., López, E., Rodriguez-Barbosa, J. I., Santamarina,
I., Filgueira, P., et al. (2005). Differentiation “in vitro” of primary and
immortalized porcine mesenchymal stem cells into cardiomyocytes
for cell transplantation. Transplant. Proc. 37, 481–482. doi:
10.1016/j.transproceed.2004.12.247
Moussaieff, A., Rouleau, M., Kitsberg, D., Cohen, M., Levy, G., Barasch, D., et al.
(2015). Glycolysis-mediated changes in acetyl-CoA and histone acetylation
control the early differentiation of embryonic stem cells. Cell Metab. 21,
392–402. doi: 10.1016/j.cmet.2015.02.002
Pattappa, G., Heywood, H. K., de Bruijn, J. D., and Lee, D. A. (2011). The
metabolism of human mesenchymal stem cells during proliferation and
differentiation. J. Cell. Physiol. 226, 2562–2570. doi: 10.1002/jcp.22605
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A., et al. (2008).
Mesenchymal stem cell-mediated immunosuppression occurs via concerted
action of chemokines and nitric oxide. Cell Stem Cell 2, 141–150. doi:
10.1016/j.stem.2007.11.014
Ries, C., Egea, V., Karow, M., Kolb, H., Jochum, M., and Neth, P. (2007). MMP-
2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human
mesenchymal stem cells: differential regulation by inflammatory cytokines.
Blood 109, 4055–4063. doi: 10.1182/blood-2006-10-051060
Ringdén, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lönnies,
H., et al. (2006). Mesenchymal stem cells for treatment of therapy-
resistant graft-versus-host disease. Transplantation 81, 1390–1397. doi:
10.1097/01.tp.0000214462.63943.14
Rodríguez-Prados, J. C., Través, P. G., Cuenca, J., Rico, D., Aragonés, J., Martín-
Sanz, P., et al. (2010). Substrate fate in activated macrophages: a comparison
between innate, classic, and alternative activation. J. Immunol. 185, 605–614.
doi: 10.4049/jimmunol.0901698
Ross, A. L., Leder, D. E., Weiss, J., Izakovic, J., and Grichnik, J. M. (2011). Genomic
instability in cultured stem cells: associated risks and underlying mechanisms.
Regen. Med. 6, 653–662. doi: 10.2217/rme.11.44
Schinköthe, T., Bloch, W., and Schmidt, A. (2008). In vitro secreting profile
of human mesenchymal stem cells. Stem Cells Dev. 17, 199–206. doi:
10.1089/scd.2007.0175
Stoltz, J. F., de Isla, N. Li, Y. P., Bensoussan, D., Zhang, L., Huselstein, Y., et al.
(2015). Stem cells and regenerative medicine: myth or Reality of the 21th
Century. Stem Cells Int. 2015:734731. doi: 10.1155/2015/734731
Sykova, E., and Forostyak, S. (2013). Stem cells in regenerative medicine. Laser
Ther. 22, 87–92. doi: 10.5978/islsm.13-RE-01
Uccelli, A., Laroni, A., and Freedman, M. S. (2011). Mesenchymal stem cells for the
treatment of multiple sclerosis and other neurological diseases. Lancet Neurol.
10, 649–656. doi: 10.1016/S1474-4422(11)70121-1
Visse, R., and Nagase, H. (2003). Matrix metalloproteinases and tissue inhibitors
of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92,
827–839. doi: 10.1161/01.RES.0000070112.80711.3D
Wang, M. L., Chiou, S. H., and Wu, C. W. (2013). Targeting cancer stem cells:
emerging role of Nanog transcription factor.Onco. Targets. Ther. 6, 1207–1220.
doi: 10.2147/OTT.S38114
Wei, X., Yang, X., Han, Z. P., Qu, F. F., Shao, L., and Shi, Y. F. (2013). Mesenchymal
stem cells: a new trend for cell therapy. Acta Pharmacol. Sin. 34, 747–754. doi:
10.1038/aps.2013.50
Wilson, A., Murphy, M. J., Oskarsson, T., Kaloulis, K., Bettess, M. D., Oser, G.
M., et al. (2004). c-Myc controls the balance between hematopoietic stem cell
self-renewal and differentiation. Genes Dev. 18, 2747–2763. doi: 10.1101/gad.
313104
Woodbury, D., Reynolds, K., and Black, I. B. (2002). Adult bone marrow
stromal stem cells express germline, ectodermal, endodermal, and mesodermal
genes prior to neurogenesis. J. Neurosci. Res. 69, 908–917. doi: 10.1002/jnr.
10365
Wu, S. M., and Hochedlinger, K. (2011). Harnessing the potential of induced
pluripotent stem cells for regenerative medicine. Nat. Cell Biol. 13, 497–505.
doi: 10.1038/ncb0511-497
Xu, W., Zhang, X., Qian, H., Zhu, W., Sun, X., Hu, J., et al. (2004).
Mesenchymal stem cells from adult human bone marrow differentiate into
a cardiomyocyte phenotype in vitro. Exp. Biol. Med. (Maywood). 229,
623–631
Zhang, W., Ge, W., Li, C., You, S., Liao, L., Han, Q., et al. (2004). Effects
of mesenchymal stem cells on differentiation, maturation, and function of
human monocyte-derived dendritic cells. Stem Cells Dev. 13, 263–271. doi:
10.1089/154732804323099190
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Prieto, Fernández-Velasco, Fernández-Santos, Sánchez, Terrón,
Martín-Sanz, Fernández-Avilés and Boscá. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 12 November 2016 | Volume 7 | Article 548
